Sugi Predict

Sugi Predict / Compounds / SCHEMBL2284397

SCHEMBL2284397

SCHEMBL2284397

O=c1ccn(Cc2ccccc2)c(=S)[nH]1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DBH P09172 2/20 0.57
▸ ALDH1A1 P00352 2/20 0.57
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ DUT P33316 2/20 0.44
▸ HPGD P15428 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ TP53 P04637 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ HDAC8 Q9BY41 1/20 0.44
▸ HDAC6 Q9UBN7 1/20 0.44
▸ LGMN Q99538 1/20 0.43
▸ MTNR1A P48039 1/20 0.43
▸ MTNR1B P49286 1/20 0.43
▸ APOBEC3G Q9HC16 1/20 0.42
▸ MAPK14 Q16539 1/20 0.42
▸ NOTUM Q6P988 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7004992 0.83 ALDH1A1 (0.41) DBHALDH1A1HPGDKDM4EHDAC8
SCHEMBL6426711 0.83 KMT2A (0.59) MEN1KMT2ADUTKDM4ESMN1; SMN2
SCHEMBL2800300 0.82 DUT (0.59) ALDH1A1DUTHPGDMAPK14CYP3A4
SCHEMBL5792152 0.76 CRBN (0.42) ALDH1A1DUTTP53MTNR1AMTNR1B
SCHEMBL8656960 0.74 PKM (0.45) ALDH1A1DUTKDM4ESMN1; SMN2LGMN
SCHEMBL1673256 0.74 KMT2A (0.42) ALDH1A1MEN1KMT2ADUTKDM4E
SCHEMBL17219548 0.73 DBH (0.35) DBHDUTCYP3A4
SCHEMBL11079680 0.73 DBH (1.00) DBHALDH1A1KMT2AHPGDCYP3A4
SCHEMBL23323360 0.71 CRBN (0.38) ALDH1A1DUTMTNR1AMTNR1B
SCHEMBL11581000 0.71 ALDH1A1 (0.43) ALDH1A1DUT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 — — US disclosed
US-9642809-B2 Controlled release pharmaceutical compositions for prolonged effect EGALET LTD. (GB) 2017-05-09 — — US disclosed
US-9587016-B2 Treatment method for lung remodeling diseases FIBROGEN, INC. (US) 2017-03-07 — — US disclosed
CN-106255414-A S benzylthiouracil compound and the method strengthening plant root growth 瓦伦特生物科学公司 2016-12-21 — — CN disclosed
CN-106255414-A S benzylthiouracil compound and the method strengthening plant root growth 瓦伦特生物科学公司 2016-12-21 — — CN disclosed
CN-106255414-A S benzylthiouracil compound and the method strengthening plant root growth 瓦伦特生物科学公司 2016-12-21 — — CN disclosed
US-9510593-B2 S-benzylthiouracil compounds and methods of enhancing plant root growth VALENT BIOSCIENCES CORPORATION (US) 2016-12-06 — — US disclosed
EP-3094181-A1 S-BENZYLTHIOURACIL COMPOUNDS AND METHODS OF ENHANCING PLANT ROOT GROWTH Valent Biosciences Corporation (US) 2016-11-23 — — EP disclosed
US-9499535-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2016-11-22 — — US disclosed
EP-2699572-B1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2016-08-10 — — EP disclosed
EP-1028955-B1 PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SMITHKLINE BEECHAM PLC (GB) 2003-07-16 — — EP disclosed
US-20020120139-A1 Pyrimidinone compounds and pharmaceutical compositions containing them HICKEY DEIRDRE MARY BERNADETTE (GB) 2002-08-29 — — US disclosed
US-6417192-B1 DRUGS WITH PYRIMIDONE COMPOUNDS INHIBITORS OF THE ENZYME LDL PLA.SUB.2 AND THEREFORE OF USE IN TREATING ATHEROSCLEROSIS. SMITHKLINE BEECHAM P.L.C. (GB) 2002-07-09 — — US disclosed
EP-1169310-A1 PROCESS FOR PREPARING MKC-442 Triangle Pharmaceuticals Inc. (US) 2002-01-09 — — EP disclosed
WO-2000061566-A1 PROCESS FOR PREPARING MKC-442 TRIANGLE PHARMACEUTICALS, INC. (US) 2000-10-19 — — WO disclosed
EP-1028955-A1 PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SmithKline Beecham p.l.c. (GB) 2000-08-23 — — EP disclosed
WO-1999024420-A1 PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SMITHKLINE BEECHAM PLC (GB) 1999-05-20 — — WO disclosed
EP-0093653-B1 PROCESS FOR THE PREPARATION OF IODO-THYRONINES AND IODO-THYROACETIC ACIDS BY ELECTROCHEMICAL REDUCTION AT A CONTROLLED POTENTIAL SPIRAL Société à responsabilité limitée dite : (FR) 1985-07-10 — — EP disclosed
US-4490221-A Process for preparing iodothyronines and iodothyroacetic acids by electrochemical reduction at controlled potential SPIRAL SOCIETE A RESPONSABILITE LIMITEE DITE (FR) 1984-12-25 — — US disclosed
EP-0093653-A1 Process for the preparation of iodo-thyronines and iodo-thyroacetic acids by electrochemical reduction at a controlled potential SPIRAL Société à responsabilité limitée dite : (FR) 1983-11-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120139-A1 Pyrimidinone compounds and pharmaceutical compositions containing them PLA2G7, PLA2G1B, PLA2G4C DBH 4128/4885ALDH1A1 960/4885MEN1 4462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.